(Total Views: 322)
Posted On: 08/20/2025 11:18:06 PM
Post# of 156156
Fantastic interview.
Jay talks about the legwork he had to do to track down what happened to patients that were part of the 3 discontinued cancer trials, contacting investigators and calling patients' families.
There were 42 patients in total, 8 are still alive, 5 are/were TNBC patients. Of those 5, 3 have no disease including 2 that had lung and lung and brain metastases. The common factor among the survivors is that blood tests showed PDL-1 inducement then those patients received PDL-1 checkpoint inhibitors. Patients that either didn't induce or didn't receive PDL-1 inhibitors fared poorly. That was the revelation for him.
Along with a lot more info on what's happening with the company, he also says that the Alzheimer's trial has FDA and IRB approval and is currently screening patients.
Jay talks about the legwork he had to do to track down what happened to patients that were part of the 3 discontinued cancer trials, contacting investigators and calling patients' families.
There were 42 patients in total, 8 are still alive, 5 are/were TNBC patients. Of those 5, 3 have no disease including 2 that had lung and lung and brain metastases. The common factor among the survivors is that blood tests showed PDL-1 inducement then those patients received PDL-1 checkpoint inhibitors. Patients that either didn't induce or didn't receive PDL-1 inhibitors fared poorly. That was the revelation for him.
Along with a lot more info on what's happening with the company, he also says that the Alzheimer's trial has FDA and IRB approval and is currently screening patients.
(11)
(0)
